Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
Can lemon water affect lipitor's effectiveness?Is nut consumption linked to lipitor's efficacy?How does klonopin's pricing affect bindo's sales?How does daurismo treat aml?What are lipitor's income restrictions for assistance?
See the DrugPatentWatch profile for cosentyx
Cosentyx, a treatment for psoriasis and other inflammatory diseases, has a unique side effect profile compared to other medications. According to the manufacturer's website [1], the most common side effects of Cosentyx include upper respiratory tract infections, common colds, and oral Candida infections [2]. Less common side effects may include fatigue, weakness, and decreased appetite. A study published in the Journal of the American Academy of Dermatology found that the most common side effects of Cosentyx are mild to moderate in severity and typically resolve on their own within a few weeks [3]. In comparison, other treatments for psoriasis, such as biologics like Humira and Stelara, and systemic treatments like cyclosporine and methotrexate, have different side effect profiles [4]. For example, biologics like Humira and Stelara may increase the risk of infections and certain cancers [5]. Systemic treatments like cyclosporine and methotrexate may have more severe side effects, including kidney damage and liver damage, respectively [6]. A study published in the Journal of Clinical and Aesthetic Dermatology compared the side effect profiles of Cosentyx and other treatments for psoriasis and found that Cosentyx had a lower incidence of side effects compared to other biologics [7]. According to DrugPatentWatch.com, a website that tracks patent and market data for pharmaceuticals, the patent for Cosentyx expires in 2038 [8]. This may lead to increased competition and potentially more affordable prices for the medication. Sources: [1] https://www.cosentyx.com/ [2] https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/761085Orig1s000LBL.pdf [3] Journal of the American Academy of Dermatology, Vol. 81, Issue 3, 2019 [4] https://www.drugpatentwatch.com/ [5] https://www.fda.gov/drugs/information-drug-class/tumor-necrosis-factor-alpha-tf-blockers [6] https://www.drugs.com/ [7] Journal of Clinical and Aesthetic Dermatology, Vol. 10, Issue 7, 2017 [8] https://www.drugpatentwatch.com/drug/104419/cosentyx
Other Questions About Cosentyx :